Cross-reactive memory T cells and herd immunity to SARS-CoV-2

[1]  W. Pegden,et al.  Individual variation in susceptibility or exposure to SARS-CoV-2 lowers the herd immunity threshold , 2022, Journal of Theoretical Biology.

[2]  P. Doshi.  Covid-19: Do many people have pre-existing immunity? , 2020, BMJ.

[3]  J. Greenbaum,et al.  Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity , 2020, Cell.

[4]  M. McElrath,et al.  COVID-19 and the Path to Immunity. , 2020, JAMA.

[5]  S. Cauchemez,et al.  COVID-19 herd immunity: where are we? , 2020, Nature Reviews Immunology.

[6]  A. Gylfason,et al.  Humoral Immune Response to SARS-CoV-2 in Iceland , 2020, The New England journal of medicine.

[7]  J. Bloom,et al.  Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate , 2020, Journal of Clinical Microbiology.

[8]  M. Altfeld,et al.  Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions , 2020, Immunity.

[9]  J. Bloom,et al.  Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate , 2020, medRxiv.

[10]  L. Carter,et al.  Functional SARS-CoV-2-specific immune memory persists after mild COVID-19 , 2020, medRxiv.

[11]  S. Mallal,et al.  Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans , 2020, Science.

[12]  V. Munster,et al.  ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques , 2020, Nature.

[13]  U. Reimer,et al.  SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19 , 2020, Nature.

[14]  M. Chen,et al.  A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction , 2020, Nature Biotechnology.

[15]  A. Firpo,et al.  SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months , 2020, medRxiv.

[16]  Martin Linster,et al.  SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls , 2020, Nature.

[17]  A. Sette,et al.  Pre-existing immunity to SARS-CoV-2: the knowns and unknowns , 2020, Nature Reviews Immunology.

[18]  Morten Nielsen,et al.  Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 , 2020, Cell.

[19]  A. Sette,et al.  Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome , 2020, Science Immunology.

[20]  Frank Ball,et al.  A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2 , 2020, Science.

[21]  X. Tang,et al.  Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections , 2020, Nature Medicine.

[22]  J. Dye,et al.  Broad neutralization of SARS-related viruses by human monoclonal antibodies , 2020, Science.

[23]  A. Sette,et al.  Single-cell transcriptomic analysis of SARS-CoV-2 reactive CD4+ T cells , 2020, bioRxiv.

[24]  M. V. von Herrath,et al.  Faculty Opinions recommendation of Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[25]  Vineet D. Menachery,et al.  Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients , 2020, Cell Reports Medicine.

[26]  R. Baric,et al.  DNA vaccine protection against SARS-CoV-2 in rhesus macaques , 2020, Science.

[27]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[28]  C. Cunningham-Rundles,et al.  A serological assay to detect SARS-CoV-2 seroconversion in humans , 2020, Nature Medicine.

[29]  Caetano Souto-Maior,et al.  Individual variation in susceptibility or exposure to SARS-CoV-2 lowers the herd immunity threshold , 2020, medRxiv.

[30]  Y. Yazdanpanah,et al.  Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients , 2020, Emerging infectious diseases.

[31]  Eric H. Y. Lau,et al.  Temporal dynamics in viral shedding and transmissibility of COVID-19 , 2020, Nature Medicine.

[32]  Yonatan H. Grad,et al.  Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period , 2020, Science.

[33]  Sandeep Kumar Dhanda,et al.  T Cell Responses Induced by Attenuated Flavivirus Vaccination Are Specific and Show Limited Cross-Reactivity with Other Flavivirus Species , 2020, Journal of Virology.

[34]  S. Crotty.  T Follicular Helper Cell Biology: A Decade of Discovery and Diseases. , 2019, Immunity.

[35]  D. Masopust,et al.  Tissue-Resident T Cells and Other Resident Leukocytes. , 2019, Annual review of immunology.

[36]  R. Baric,et al.  Airway Memory CD4+ T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses , 2016, Immunity.

[37]  John T. Chang,et al.  Molecular regulation of effector and memory T cell differentiation , 2014, Nature Immunology.

[38]  A. Iwasaki,et al.  A local macrophage chemokine network sustains protective tissue-resident memory CD4 T cells , 2014, Science.

[39]  T. Merkel,et al.  Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model , 2013, Proceedings of the National Academy of Sciences.

[40]  Jonathan J Deeks,et al.  Cellular immune correlates of protection against symptomatic pandemic influenza , 2013, Nature Medicine.

[41]  Joel C. Miller,et al.  A Note on the Derivation of Epidemic Final Sizes , 2012, Bulletin of mathematical biology.

[42]  J. Oxford,et al.  Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans , 2012, Nature Medicine.

[43]  E. Wherry,et al.  Cutting Edge: Tissue-Retentive Lung Memory CD4 T Cells Mediate Optimal Protection to Respiratory Virus Infection , 2011, The Journal of Immunology.

[44]  Bjoern Peters,et al.  Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population , 2009, Proceedings of the National Academy of Sciences.

[45]  P. E. Kopp,et al.  Superspreading and the effect of individual variation on disease emergence , 2005, Nature.

[46]  J. Robins,et al.  Transmission Dynamics and Control of Severe Acute Respiratory Syndrome , 2003, Science.

[47]  G. Davies,et al.  Knowns and Unknowns , 2003 .

[48]  M. Lipsitch,et al.  Virulence and transmissibility of pathogens: what is the relationship? , 1997, Trends in microbiology.

[49]  D. Tyrrell,et al.  The time course of the immune response to experimental coronavirus infection of man , 1990, Epidemiology and Infection.

[50]  S. Reed.  The behaviour of recent isolates of human respiratory coronavirus in vitro and in volunteers: Evidence of heterogeneity among 229E‐related strains , 2005, Journal of medical virology.